11 Feb 19
Life Science Analysis: Caution prevails in 2019
Tara Raveendran, Healthcare Analyst at Shore Capital, looks back at 2018’s impressive biotech IPO market and how the tides turned going into 2019. She also provides insight on the market fundamentals and explores the improving M&A environment for small and mid-cap biotechs.
01 Feb 19
Howard Shore on Bloomberg Surveillance, 1 February 2019
Howard Shore discusses his support for the Conservative party and his thoughts on Brexit, including the possibility of a hard Brexit, a hard border for Ireland and the scope for compromise.
Howard Shore on Bloomberg Surveillance
28 Jan 19
Response to media speculation
28 January 2019
Shore Capital Group Limited ("Shore Capital" or the "Company") - response to media speculation
Shore Capital, the independent investment group specialising in capital markets, fund management and principal finance notes the recent media speculation regarding the poten